NEW YORK (GenomeWeb News) – BioMarker Strategies, a molecular diagnostics developer focused on tumor testing, has won a Small Business Innovation Research grant from the National Cancer Institute.

The Fast-Track SBIR grant gives the company an initial award of $254,000, a number that could increase by up to $2 million after the initial phase of the work is completed, the firm said.

The company plans to use the funds to "expedite production" of a prototype of its SnapPath live-tumor cell testing system, BioMarker Strategies CEO Karen Olson said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.